Conclusions LVSIs, tumours size and depth of invasion were the most important risk factors of pN+. Based on that, we identified a group at very low risk of pN+, in whom sentinel lymph node mapping should be considered to replace radical pelvic lymphadenectomy.

2022-LBA-1703-ESGO


1Vanessa Samouëlian, 2Audrey Feng-Emond, 3Béatrice Cormier, 4Thomas Warkus, 5Omar Moreira Bacha, 6Elise de Castro Hillmann. 1Gynecology oncology, CHUM, Montreal, QC, Canada; 2Faculté de Médecine, Université de Montréal, Montréal, QC, Canada; 3Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 4Gynecology oncology, CHUM Research Center, Montreal, QC, Canada; 5Bioinformatics Core facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 6Medical Genetics Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 7Data Collection Core facility- GSTeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 8Epidemiology and Biostatistics core facility- GSTEpi, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy

10.1136/ijgc-2022-ESGO.1011

Introduction MIS has been abandoned in many centers for cervical cancer treatment after publication of the LACC trial in 2018. Several critics and theories emerged afterward. Our study looked at data of a single large volume institution. Disease free survival (DFS) and mortality rates were compared for both surgical approaches.

Methods We retrospectively reviewed all surgical cervical cancer cases from 2006 to 2017 of the Centre Hospitalier de l’Université de Montréal. Only patients treated by Minimal Invasive Surgery (MIS) or laparotomy were included. We compared cohorts’ characteristics and survival outcomes for MIS and laparotomy. Descriptive data is presented in means, standard deviations, and percentages. Kaplan-Meier was used to generate disease free survival (DFS) and overall survival (OS) curves; log-rank was used to compare curves. Survival outcomes of the use of intraperitoneal manipulator were also investigated. Statistical significance was 0.05.

Results 257 patients were included (94 robotic, 38 laparoscopy, 125 laparotomy). Patients’ characteristics did not significantly differ among groups. Histology was 50.6% squamous cell carcinoma, 35.4% adenocarcinoma, 3.9% adenosquamous and 10.1% other subtypes. Patients were FIGO stages IA (51.0%), IB (43.1%) and IIa or more (5.9%). Median follow-up was 161 months. Intraperitoneal devices were used in 70.2% of the MIS group. 48.8% had no residual disease at surgery. No differences in intra-operative, post-operative complications and readmission rates between MIS and laparotomy was observed. Total cohort intra-operative and post-operative complications rates were respectively 4.5% and 25.2%. Recurrence rates and death rates were significantly lower for MIS than for laparotomy approach (respectively 1.5% vs 8.1%, p=0.013, 1.5% vs 4.8%, p=0.043). Disease-specific mortality rate did not statistically differ (MIS=1.5%, laparotomy =4.8%, p=0.121).

Conclusions Selected cervix cancer patients may benefit from MIS. Further studies are needed.

2022-LBA-746-ESGO

IMPLEMENTATION OF A COMPREHENSIVE CANCER GENOME PROFILING PROGRAMME INTO CLINICAL PRACTICE: AN ITALIAN EXPERIENCE IN A REFERRAL CENTRE FOR GYNECOLOGICAL CANCERS

1Camilla Nero, 2Silvia Pelligra, 3Simona Duranti, 4Flavia Giacomini, 5Floriana Camarda, 6Elena Giudice, 7Alessia Piemonte, 8Francesca Silano, 9Angelo Milimici, 10Maria de Boris, 11Giuseppina Raspiagio, 12Luciano Giaco, 13Emanuela Luci Cordisco, 14Marta de Donato, 15Tina Pasciuto, 16Diana Giannarelli, 17Francesco Fanfani, 18Gian Franca Zannoni, 19Anna Fagotti, 20Domenica Lorusso, 21Giovanni Scambia. 1Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 2Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 3Gynecologic Oncology and Breast Pathology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 4Gynecologic Oncology, CHUM Montreal, Quebec, Canada; 5Diagnostic Imaging Core Facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 6Medical Genetics Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 7Genomics Core facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 8Bioinformatics Core facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 9Biostatistics core facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 10Epidemiology and Biostatistics core facility- GSTeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 11Biostatistics core facility- GSTeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 12Bioinformatics Core Facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 13Gynecologic Oncology, CHUM Montreal, Quebec, Canada; 14Bioinformatics Core Facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 15Bioinformatics Core Facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 16Bioinformatics Core Facility, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 17Data Collection Core facility- GSTeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 18Biostatistics core facility- GSTeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 19Epidemiology and Biostatistics core facility- GSTeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy

10.1136/ijgc-2022-ESGO.1012

Introduction The implementation of cancer molecular characterization in clinical practice has improved prognostic re-definition extending the eligibility to a continuous increasing number of targeted treatments. A molecular based primary tumor agnostic approach, could satisfy this purpose. Although in 2020 the European Society of Medical Oncology recommended comprehensive genomic profiling (CGP) implementation at least in academic centers many challenges have to be acknowledged.

Methods In the present monocentric interventional prospective study, ten cancer types including ovarian and endometrial cancer treated at our Institution from January 2022, were identified and profiled using a FPG500 molecular platform. An analysis was designed to evaluate the feasibility of CGP from Formalin-Fixed Paraffin-Embedded specimens, turnaround times, presence of targetable alteration as well as a description...
of the mutational landscape, enrollment rate in clinical trials, indications for referral to genetic counseling. Molecular features were further correlated with available clinico-pathological variables for each disease type.

Results Out of 188 women, the feasibility of CGP was 98%, with a mean turnaround time of 39 days. 33.5% of the population was referred to genetic counselling. Most significant findings are reported in Table 1.

Conclusions Regarding ovarian cancer, as expected, endometrioid and clear cell histotypes had different mutational profiles compared to serous ones (KRAS, ERBB2, FGFR7, LRP1B, MDC1 and SPEN vs BRCA 1, FGFR2, FGFR7, FGFR3, TP53 respectively) with a minimum incidence of mutations. Regarding endometrial cancer, no difference was observed in clinical features for patients with TMB>10. No difference was observed between patients younger or older than 50 years. A TMB>10 was found in 35% of patients with 475 altered genes (mean=28) the most frequent being PTEN (82%), ARID1A (71%), and PIK3CA (65%).

**2022-LBA-718-ESGO**

**SENTINEL NODE BIOPSY FOR ENDOMETRIAL CANCER BY RETROPERITONEAL TRANSVGINAL NATURAL ORIFICE TRANSLUMINAL ENDOSCOPIC SURGERY**

1,2Daniela Huber, 2Yannick Hurni. 1Obstetrics and Gynecology, Valais Hospital, Sion, Switzerland; 2Pediatrics, Obstetrics and Gynecology, Geneva University Hospital, Geneva, Switzerland

Introduction Surgical staging with sentinel lymph node biopsy (SLNB) is an important tool to guide the management of early-stage endometrial cancer. This staging is generally performed by minimally invasive techniques such as conventional, single-site, or robotic laparoscopy. To further reduce the morbidity related to transabdominal surgeries, SLNB by total retroperitoneal transvaginal natural orifice transluminal endoscopic surgery (vNOTES) was recently introduced at our institution. Here, we describe how to perform this surgical technique and we report our preliminary results.

**Methods** Indocyanine green was injected into the cervix to identify sentinel lymph nodes (SLNs). Access to the pelvic retroperitoneal space was achieved through a paracervical incision in the lateral vaginal fornix, providing access to the obturator fossa. A 7 cm GelPort transvaginal access platform was used as a vNOTES port, and CO₂ was insufflated to expand the retroperitoneal space. SLNs were identified using fluorescence imaging, carefully resected, and removed transvaginally.

**Results** Eleven patients underwent SLNB by vNOTES at our institution between October 2021 and July 2022. Indications to perform SLNB were endometrial cancer (8 cases) and endometrial complex atypical hyperplasia (3 cases). The median operative time was 113 (81–211) minutes. The median estimated blood loss was 20 (20–400) mL. The overall bilateral detection rate was 100% (10/10). We completed all procedures without significant intraoperative complications, but 1 case required conversion to conventional laparoscopy. The median postoperative stay was 2 (2–4) days. We observed one case of postoperative deep vein thrombosis and an asymptomatic vaginal vault hematoma in one patient and a retroperitoneal hematoma requiring surgical drainage in another. Definitive results are not available at the time of abstract submission and will be updated later.